Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Plasmodium falciparum haem detoxification pathway is a critical biological process that enables the malaria parasite to survive within human red blood cells. During its intraerythrocytic stage, the parasite digests host hemoglobin in an acidic digestive vacuole (DV), releasing large amounts of free haem (ferriprotoporphyrin IX, Fe(III)PPIX). Free haem is highly toxic due to its ability to generate reactive oxygen species and disrupt cellular membranes. To avoid toxicity, *P. falciparum* rapidly converts free haem into an inert crystalline pigment called hemozoin. Several antimalarial drugs act by disrupting this pathway: Chloroquine and Artemisinin-based drugs.
Inhibition of hemozoin formation, leading to accumulation of toxic free haem
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Plasmodium falciparum Haem Detoxification Pathway.